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ASCT  autologous stem cell transplantation 
CI            confidence interval 
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REAL    Revised European-American Classification of Lymphoid Neoplasms 
SCNSL   systemic CNS lymphoma 
WHO      World Health Organisation
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94. INTRODUCTION
This thesis deals with clinical aspects of extra nodal manifestations of non-Hodgkin’s 
lymphoma (NHL) of patients treated at the Norwegian Radium Hospital. Paper I and II 
describes clinical symptoms and outcome in lymphoma patients with manifestations of 
the central nervous system (CNS) from systemic lymphoma (paper I) and investigates 
risk factors for developing CNS disease (paper II). In paper III and IV, we have 
investigated the outcome and long term side effects of the treatment involving primary 
surgery in patients with primary involvement of the gastric ventricle. 
 
Extranodal non-Hodgkin`s lymphomas arise from tissues other than lymph nodes. 
These lymphomas constitute 25% of all lymphomas in North America compared to 30-
48% in Western Europe (Freeman et al. 1997, Glass et al. 1997, Otter et al. 1989, 
D’Amore et al. 1991).  
Primary CNS lymphoma is defined as isolated lymphoma involvement of the CNS and 
constitutes only 1-2% of all non-Hodgkin’s lymphomas (Krogh-Jensen et al. 1994). In 
most cases, the manifestation presents as parenchymatous intracerebral lesions, but 
isolated cerebrospinal fluid (CSF) involvement may occur. Primary CNS lymphomas are 
not discussed further in this thesis. 
CNS involvement at the time of diagnosis of systemic lymphoma most often involves the 
CSF. Progression or relapse in CNS is a feared complication, and occurs both in the 
brain parenchyma and in the CSF. Its occurrence is described in detail in paper I and II. 
The gastrointestinal tract (GIT) is the most common primary extranodal localization, 
accounting for 12-13 % of all NHL and 30-40% of all extranodal sites (Herrmann et al. 
1980, d’Amore et al. 1994). 
The incidence of NHL has increased during the last decades, with 852 new cases of 
NHL in Norway in 2006 (Cancer Registry of Norway). 
 
4.1 Lymphoma classifications
Various lymphoma classifications have been used in the Western world during the last 
decades, but in Norway at the time this thesis was performed, the updated Kiel 
classification was used (Stansfeld et al. 1988). This classification divides the lymphoma 
entities based on their presumed cell of origin. In essence the diagnosis is based on 
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light microscopic histological examinations. Standard formalin-fixed haematoxylin-eosin 
stained slides are used. In addition, T-and B-cell origin of the lymphomas have been 
examined on either immunostained formalin fixed slides or mononuclear cell 
suspensions prepared from the lymphoma biopsies. It also divided the histologies into 
low- and high grade disease based on their clinical aggressiveness (Brittinger et al. 
1984). 
In 1999, The World Health Organisation (WHO) Classification of Hematologic 
Malignancies was published (Jaffe et al. 2001). This classification was largely based on 
The Revised European-American Classification of Lymphoid Neoplasms (REAL),  a 
lymphoma classification suggestion published in 1994 (Harris et al. 1994). Each disease 
was defined by morphology and more detailed immunophenotype as well as molecular 
characteristics and clinical features. The WHO classification was very soon adopted 
throughout the world. Thereby, it is possible to compare lymphoma epidemiology and 
treatment results worldwide. In paper I and II, the Kiel classification is used while in 
paper III and IV, the histology is revised according to the WHO classification. The REAL 
and WHO classification may be divided into three clinically relevant categories, indolent, 
aggressive and very aggressive disease (Hiddemann et al.1996). 
 
4.2 Staging of lymphomas
Lymphomas are staged according to the Ann Arbor classification (Carbone et al. 1971) 
with modifications (Lister et al. 1989) as listed in the following table: 
 
Stage I: Involvement of one lymph node region (spleen, thymus and Waldeyers ring are 
regarded as nodal). 
Stage II: Involvement of two or more lymph node regions on the same side of the 
diaphragm, or one or more lymph node regions on the same side of the diaphragm with 
growth into extralymphatic organ / tissue (IIE). 
Stage II suffix 1: Involvement of two neighbouring regions which can be included in one 
radiation field. 
Stage III: Involvement of lymph node regions on both side of diaphragm, or one or more 
lymph node regions on both side of the diaphragm (with growth into extranodal organ / 
tissue (IIIE). 
Stage IV: Diffuse or disseminated lymphoma in one or more extralymphatic organ / 
tissue with or without involvement of lymph nodes. 
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The suffix E for stages I-III denotes extranodal disease.  
 
The stage of the disease is an important risk factor for non-Hodgkin’s lymphoma and is 
used in treatment decisions. 
 
4.3 Disease assessment 
Treatment decision of patients with suspected lymphoma is dependent on  
- adequate relevant history with emphasis on the presence or not of B-symptoms (fever 
of unknown origin, weight loss of more than 10% of the body weight and night sweats), 
the time from the first symptoms or signs, history of infections, pain, vital functions and 
the clinical performance status 
- clinical examination with emphasis on lymph node status and the presence of other 
masses, spleen and liver enlargement, mental status, signs of neurological disease and 
vital organ examinations 
- adequate sampling of pathological masses for histopathological diagnosis 
- bone marrow biopsy and for some entities bone marrow aspirate for immunological 
assessment by flow cytometry 
- Computer tomography (CT) scans of the chest, the abdominal and pelvic regions 
- supplementary investigations, particularly of the a) cerebrospinal fluid (cell count, 
protein, glucose and flow cytometric analysis) in cases of very aggressive lymphomas 
(lymphoblastic lymphomas, Burkitt’s lymphoma) and aggressive lymphomas with risk 
factors for CNS relapse, and combined with magnetic resonance imaging (MRI) 
examinations in cases with mental deterioration or other CNS related symptoms like 
seizures and neurological findings b) alimentary tract examinations in cases of GIT- 
related symptoms and signs like hematemesis, melena and diarrhoea and in specific 
histological diagnosis often involving the alimentary tract. 
Patients are staged according to the Ann Arbor system (Carbone et al. 1971, Lister et 
al. 1989). For extranodal disease, the Nordic countries have used a Nordic classification 
system from 1997, but as this classification system is unpublished, paper III and IV 
classifies the gastric lymphomas according to Musshoff et al. (1977).  
 
4.4 Clinical risk factors 
Given the same histological entities, patients with younger age and limited disease have 
generally a better prognosis than patients at higher age and with more extensive 
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disease. Other clinical and biological risk factors (like assessment of the proliferation 
rate of the tumour assessed by the activation antigen Ki67) have been published, but 
did not achieve general acceptance. In 1994, however, an international consortium 
undertook a retrospective examination of clinical risk factors in aggressive lymphomas 
(The International non-Hodgkins lymphoma prognostic factor project,1994). During the 
last ten years, these risk factors named International Prognostic Index, IPI, have been 
used widely in risk stratification of patients with aggressive lymphomas and in 
comparing treatment results of new regimens. Similarly, another international group 
performed a similar retrospective analysis in follicular lymphoma (Solal Séligny et al. 
2004) with similar impact worldwide. This index is called Follicular Lymphoma 
International Prognostic Index. Although these prognostic indexes have not been 
applied in the papers of this thesis, they are shown in table 1 and 2.  
 
   Table 1. International Prognostic Index for aggressive lymphomas 
All ages  Patients < 60 years 
Risk factors Risk factors 
Age  > 60 years  - 
Serum LDH above normal Serum LDH above normal 
> 1 extranodal site - 
WHO status  2 WHO status  2 
Stage III/IV Stage III/IV 
 
    
 
   Table 2. Follicular Lymphoma International Prognostic Index 
Age > 60 years
Stage III/IV 
 Hemoglobin level < 120 g/L   
 Serum LDH above normal  
 Number of nodal sites > 4 
 
 
For both the IPI and the FLIPI scores, the individual risk factors are largely of the same 
relative risks. For estimating the total risk, the individual factors are simply added. 
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4.5 Summary of general treatment recommendations
The first line treatment recommendations at the Norwegian Radium Hospital for the 
period 1990 – 2000 are briefly summarized as follows: 
 
Indolent lymphomas (or low grade lymphomas according to the Kiel classification), 
stage I and stage II for those patients with adjacent lymph node involvement were given 
high energy radiotherapy, 40 Gy / 20 fractions. Patients with extensive disease without 
symptoms requiring therapy were observed until treatment requirements were met: B-
symptoms, cytopenias or lymph node enlargement with symptoms of discomfort or with 
impaired  organ function like medullary compression or uretheral obstruction. When 
these requirements were met, patients were most often given chlorambucil monotherpy 
(for some patients in combination with steroids).  
 
High grade lymphomas stage I and stage II as defined on page 8  were given 3 – 6 
courses of CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, 
prednisone), followed by radiotherapy, 40 Gy. Patients with extensive disease were 
generally given CHOP chemotherapy alone. 
 
Very aggressive lymphomas (lymphoblastic lymphomas and Burkitt lymphomas) were 
until 1990 given CHOP chemotherapy, 4 courses with intrathecal methotrexate and high 
dose i.v methotrexate, 2 g /m2 with folinic acid resque at week 2 between 3-weekly 
CHOP. Patients achieving a good partial remission were consolidated with high dose 
therapy with autologous stem cell support (HDT with ASCS). After 1990, patients with 
lymphoblastic lymphomas were given induction chemotherapy with regimens as given 
for acute lymphoblastic leukemias and those with Burkitt lymphomas a regimen adopted 
from a German protocol for children with Burkitt leukaemia / lymphoma. Both of these 
very aggressive lymphomas were still consolidated with HDT with ASCS. 
 
4.5.1 Treatment recommendations for patients with systemic lymphoma with CNS 
involvement at diagnosis 
Most of these patients had aggressive or very aggressive lymphoma and were treated 
as for very aggressive lymphomas. Patients with aggressive lymphomas with 
progression in the CNS or CNS relapse were also generally given the same treatment 
regimen with intensified i.t. therapy combined with systemic therapy with CNS 
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penetration (high dose methotrexate in some cases combined with high dose 
cytarabine). The few patients who received a complete remission were consolidated 
with HDT with ASCS and irradiation to the CNS axis. 
 
Earlier studies (Herman et al. 1979, Litam et al. 1979, Ersboll et al. 1985, Wolf et al. 
1985, Liang et al. 1990) have described specific organ involvement as risk factors for 
CNS relapse (ocular orbit, paranasal sinuses, bone, testis and bone marrow). Patients 
with these risk factors were given i.t methotrexate prophylaxis, in younger patients 
combined with high dose methotrexate with folinic acid resque.  
 
4.5.2 Patients with primary CNS lymphomas  
These patients were not included in this thesis. They were for the first time period 
treated with high dose methotrexate, 2-3 g/m2 4-6 courses and consolidated with high 
energy radiotherapy to the brain, 40 Gy/20 fractions. During the later time periods, these 
patients were included in a Nordic protocol for PCNSL (Goldkuhl et al. 2002) or treated 
according to a protocol developed at Memorial Sloan-Kettering Cancer Centre. (Abrey 
et al. 2000). 
 
 
4.6. Primary surgery for gastric lymphomas
Patients with primary extranodal lymphomas followed generally the outlines described 
above. However, a different approach was used for patients with lymphomas involving 
the gastric ventricle. Due to reports of high frequency of serious bleeding or gastric 
perforations after initiation of primary chemotherapy (Fleming et al. 1982) a protocol 
was initiated in 1990, involving primary gastric surgery when technically feasible. The 
inclusion criteria and the treatment are outlined in paper III and IV. Most patients with 
indolent lymphomas with only superficial gastric wall involvement were generally not 
operated on.  
There are different surgery procedures, and the chosen method depends on where the 
lymphoma is localized. If the lymphoma is distal, partial gastrectomy can be performed, 
Bilroth I or Bilroth II (figure 1 and figure 2). The stomach will be smaller after the 
operation, but the cardiac sphincter will be preserved. If the lymphoma is in the middle 
of the stomach, the entire stomach is removed, but the bile duct and pancreatic duct 
continues to drain into the duodenum. The total gastrectomy operation is called Roux-
15
en-Y (figure 3). (Cancer Research UK 2002, Cancer Research UK Charity Number 
1089464). 
 
 
 
 
 
 
 
 
Figure 1. Partial gastrectomy ad modum Bilroth 1. 
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Figure 2. Partial gastrectomy ad modum Bilroth 2. 
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Figure 3. Total gastrectomy ad modum Roux-en-Y. 
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4.6.1 Examinations of long term side effects after primary surgery for gastric lymphomas 
Recently, the recommendation of performing primary surgery in gastric lymphomas has 
been largely abandoned due to several reasons as described in paper III and IV:  
1. The risk of gastric perforation or serious bleeding after primary chemotherapy seems 
to be lower than previously described. Furthermore, the effect of chemotherapy alone 
seems as effective as combined surgery and radiotherapy (Al Akwaa et al. 2004, Yoon 
et al. 2004, Koch et al. 2001 and 2005, Binn et al. 2003).  
2. In marginal zone lymphoma, stage IE the association of the disease with H. pylori 
infection and the effect of H.pylori eradication with antibiotics is effective in two thirds of 
the cases (Bertoni et al. 2005).  
3. Long term morbidity after primary gastric surgery has evolved as a major concern in 
carcinoma patients operated for gastric carcinomas. 
There was, however, no study which had studied the long term health status of gastric 
lymphoma patients after surgery. Consequently, we undertook a cross-sectional follow 
up examination of the patients several years after they were treated according to the 
protocol, examining the patients´ nutritional status and quality of life. In addition, a 
gastroscopy was performed, and the overall results of the treatment protocol were 
investigated. The patients were informed of the results of the investigation, and advices 
as to supplementary therapy were given by mail when indicated. 
   
4.7 Health related quality of life in cancer patients
During the two last decades, there has been an increasing focus on health related 
quality of life (HRQOL) after treatment for cancer. HRQOL focuses on the subjective 
experiences of the disease, the treatment and its side effects. Quality of life (QOL) 
studies gives a more comprehensive view of the lives of cancer patients than remission 
rates and survival analyses alone. In many phase III studies, comparing established 
therapy with a new and hopefully better therapy, QOL analysis is often integrated in the 
protocols.  
HRQOL is defined as a multidimensional concept, consisting of at least physical, 
psychological and social phenomena (Aaronsen 1991, Cella et al. 1993). The domains 
are further divided into various dimensions (physical, social and occupational function, 
emotional well-being, intimacy issues). The patient is the most reliable source for the 
HRQOL concept, which is subjective in its nature (Aaronson 1991, Cella et al. 1993). A 
low correlation between the nurses and the doctor’s conception of the well-being of the 
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patient and the patient’s own rating has been documented (Slevin et al. 1988, 
Sprangers et al. 1992). HRQOL is therefore usually investigated by using validated 
questionnaires. 
 
4.8 Examinations of the nutritional status after primary surgery for gastric 
lymphoma
The most common deficiencies after total gastrectomy (TG) and partial gastrectomy 
(PG) is related to iron, folic acid, vitamin B12 and fat indigestion with steatorrhoea, 
weight loss, vitamin D and vitamin K loss. Except for vitamin K status, these factors 
were all examined.  
The metabolic deficiencies developing two or more years after total gastrectomy 
continually aggravates, i.e. anaemia, osteoporosis / osteomalaci and loss of body 
weight (Murawa et al. 2006). In addition to disturbance of the absorption in the 
gastrointestinal tract, the patients also have a problem with inadequate calorie intake – 
due to absence of hunger, dyspepsia secondary to agastria, alteration of intestinal 
mobility, and early satiety (Braga et al.1990). 
Most studies concerning the nutritional status after gastrectomy have been studies on 
gastric cancer as these are more frequent than gastric lymphoma. Gastric cancer has a 
disease-specific 5 year survival less than 30% (Paimela et al. 2005). Patients with 
lymphoma in the gastric ventricle live for a considerably longer time; 70-80 % are alive 
after five years when the disease is limited at diagnosis. It is thus important to take care 
of and follow up the nutritional status for these lymphoma patients with dietary 
education and – advices for many years. 
 
4.8.1 Albumin 
The plasma level of albumin is a common nutritional index. Albumin is however, not a 
sensitive indicator of early malnutrition, and in addition, there are several mechanisms 
that compensate for low level of serum albumin (Waterlow 1972).  
 
4.8.2 Body Mass Index 
The nutritional status of the patients was also examined by estimation of body mass 
index (BMI, body weight / square height in m), which is another measure of general 
nutrition status. As the body weight and height was available from the time of the 
diagnosis, we were able to measure the gain or loss in BMI. 
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4.8.3 Vitamin B12 / folic acid / homocysteine 
The absorption of vitamin B12 (cobalamin) is dependent on binding to the intrinsic factor, 
a glycoprotein produced in the mucosa in the gastric ventricle. The complex is absorbed 
in the small intestine. 1-3% vitamin B12 can be absorbed by simple diffusion without the 
intrinsic factor (reviewed in Nes et al. 1998). Regularly injections of vitamin B12 are 
recommended after gastric surgery. Deficiency of vitamin B12 leads to megaloblastic 
anaemia, which also can be caused by lack of folic acid. In that case, it is very important 
never to give folic acid alone, but always together with vitamin B12 to avoid neurological 
symptoms, as folic acid may cover the symptoms of vitamin B12 deficiency. 
Homocysteine is an endogen amino acid, made in the cells by transformation from the 
essential amino acid metionin. The intracellular turnover of homocystein depends 
mainly on folic acid, vitamin B12 and vitamin B6. If one or more of the homocysteine 
metabolizing pathways are inhibited due to enzymatic defects or vitamin deficiencies, 
homocysteine accumulates, thereby causing an increased level of homocysteine in the 
plasma (reviewed in Refsum et al. 1998). Homocysteine is a highly reactive substance, 
and high levels can damage the endothelium and contribute to development of 
atherosclerotic coronary heart disease (reviewed in Stakkestad et al. 2000). Refsum et 
al. (1998), has reviewed the literature on homocysteine in relation to cardiovascular 
disease. They conclude that an elevated level of total homocysteine in blood is a 
prevalent and strong risk factor for atherosclerotic vascular disease in the coronary, 
cerebral, and peripheral vessels, and for arterial and venous thromboembolism. 
Elevated homocysteine confers a graded risk with no threshold, is independent of but 
may enhance the effect of the conventional risk factors, and seems to be a particularly 
strong predictor of cardiovascular mortality.  
Nygard et al. (1997) prospectively investigated the relation between plasma total 
homocysteine levels and mortality among 587 patients with angiographically confirmed 
coronary artery disease. They concluded that plasma total homocysteine levels are a 
strong predictor of mortality in these patients. 
 
4.8.4 Iron 
Intact epithelial cells in the GIT and normal production of gastric acid are important in 
the absorption of iron in the small intestine. Most of the non-heme iron in the food exists 
as a salt with Fe3+. In the acid environment, the inorganic iron salt will be ionized into 
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Fe3+, and when reduced to Fe 2+ (with help from i.e. vitamin C ) it is more easily 
absorbed. 
According to Roviello et al. (2004), iron deficiency following a gastrectomy is due to 
accelerated passage of food through the intestine, resulting in an insufficient time of 
contact between the absorbing mucosa and the contains of the lumen (Murawa et al. 
2006, Stael von Holstein et al. 1991). Reduced gastric acidity can also contribute to less 
absorption (Murawa et al. 2006). In addition, in patients with chronic gastritis of the 
gastric stump, small but repeated areas of bleeding from lesions of small mucosal 
vessels increase the loss of iron in the intestines. 
 
4.8.5 Vitamin D and calcium absorption  
 
The photosynthesis of vitamin D in the skin, and vitamin D`s biochemistry 
Vitamin D can be made by the influence of ultraviolet (UV) radiation through the 
sunlight, or supplied through the diet. 
7- dehydrocholesterol is made in the skin, the production is decreasing with age due to 
a thinner skin. 7-dehydrocholesterol absorbs UV radiation and converts into the pre-
vitamin D3 in a thermic reaction. Vitamin D3 (from the skin or the diet) is transported to 
the liver and hydrolyzed to 25-OH- vitamin D3 (calcidiol). This metabolite is a reliable 
indicator of the vitamin D status, and is thus the recommended metabolite to be 
measured (normal serum range 30-100 nmol/l). Calcidiol is then transported to the 
kidneys, and transformed into 1, 25-(OH)2 vitamin D3 (calcitriol) by the enzyme 25-
hydroxyvitamin D1 alfa-hydroxylase. The activity of this enzyme is stimulated positively 
by parathormone (PTH), hydrogen-, phosphate- and calcium iones, estrogen, prolactin, 
insulin, calcitonin, growth hormon and glucocorticoids, and is inhibited by calcitriol itselfs 
(reviwed in Moan et al. 2006). Calcitriol is the active hormone in the regulation of 
calcium and phosphate in the blood. Vitamin D`s biochemistry is illustrated in Figure 4 
(reviewed in Moan et al. 2006 and Nes et al. 1998). 
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Figure 4. Vitamin D`s biochemistry. 
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Functions of vitamin D
The major function of vitamin D is to maintain calcium homeostasis.  
Vitamin D is necessary for normal mineralization of the skeleton, by stimulating the 
absorption of calcium in the intestine. PTH stimulates the release of calcium from the 
skeleton (by influencing the osteoclast activity) and thereby raising the concentration of 
calcium in the blood. A low calcium or phosphate stimulates the secretion of PTH, which 
in turns stimulates the production of 1,25 (OH)2 D3 in the kidneys (reviewed in Nes et al. 
1998 and Moan et al. 2006). 
 
Absorption
Vitamin D in the diet is absorbed together with fat, and is then transported to the liver 
bound to vitamin D-binding protein. Most of the vitamin D is stored in the fat tissue. For 
those who are gastrectomized, the malabsorption of fat affects the absorption of vitamin 
D and thereby reduced calcium absorption. The reason for fat malabsorption is largely 
unclear. Factors associated with this condition after total gastrectomy are insufficient 
acid production and insufficient mixing of food and digestive juices, rapid intestinal 
passage and altered bacterial flora in the small intestine (Stael von Holstein et al. 1991, 
Bae et al. 1998). 
 
5. AIMS 
The thesis focuses on clinical aspects of extranodal manifestations of non-Hodgkin’s 
lymphoma in the CNS and the gastric lymphoma. All patients have been examined, and 
treated according to protocols at the Norwegian Radium Hospital during the last two 
decades of the previous century. 
The main objectives of the studies were: 
1) Examine the outcome of the patients with NHL with systemic involvement of the 
CNS, in order to evaluate our treatment strategy.  
2) To determine the incidence and risk factors for CNS relapse in patients with NHL. 
3) For patients with lymphoma in the GIT treated according to a protocol utilizing 
primary gastric surgery to examine the quality of life at a cross-sectional 
examination. 
4) For the same patient cohort as in 3) to examine the nutritional status. 
24
6. PATIENTS AND METHODS 
6.1 Patients
All patients were admitted, examined and treated at The Norwegian Radium Hospital 
(NRH) during the time period 1980 – 1999. They all had a diagnosis of non-
Hodgkin’s lymphoma, based on histopathological examinations at the institution. The 
hospital had the responsibility for lymphoma patients for approximately 2 mill. 
inhabitants. Patients with a curative treatment intent were admitted, based on the 
general policy at the Health Region. Patients included in the investigations on 
systemic CNS manifestations were diagnosed and treated during the period 1980 – 
1996 and the patients with gastric lymphoma during the period 1990 – 1999.  
 
6.1.1 Patients with CNS manifestations after a diagnosis of non-Hodgkin’s          
lymphoma 
2561 patients with NHL were diagnosed and treated at the NRH from 1980 to 1996. 
170 of these patients had CNS involvement (6.6%), 30 of these had primary CNS 
involvement and the remaining 140 had systemic CNS lymphoma, the latter group 
being the patients at investigation in paper I. Thirty of these patients had CNS 
manifestations at diagnosis, 27 patients at relapse and 83 patients at progression. 
   
6.1.2 Patients at risk for CNS relapse or progression 
2514 patients were included, excluding patients with PCNSL and with systemic CNS 
manifestations at diagnosis. The survivors were followed for a median observation 
time of 94 months.  
 
6.1.3 Cross-sectional follow-up study of patients with primary involvement of the 
gastric ventricle 
A total of 120 patients with involvement of the gastric ventricle were retrieved from 
the database. The overall treatment results reflect that only 40 patients (33%) had 
localized disease. The median age of the patients at diagnosis was 63 years. The 
inclusion criteria for the cross-sectional study were as follows: Patients aged 16-80 
years treated according to the standard protocol at NRH during the period from 
1990-1999, age below 80 years and in complete remission (CR) at follow up, no 
prior history of cancer, fluency in oral and written Norwegian and written informed 
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consent. The study was approved by the institutional review board at NRH and 
Norwegian Social Science Data Services. A total of 40 patients met the inclusion 
criteria, 36 patients completed the QOL questionnaires while 33 patients met for the 
clinical examination.  
 
6.2 Methods 
The patients were registered prospectively in a clinical lymphoma database using 
software from DataEase (DataEse International LTD., Romford, UK, 1991), including 
the following variables: 
 
-name and birth number 
-histopathological diagnosis 
-relevant information from staging procedures before treatment initiation including 
details concerning sites of lymphoma involvement, performance status, blood test 
results, largest tumour mass, IPI score 
-date of and details concerning initiation of primary treatment 
-response to primary treatment  
-date of first relapse or progression and details concerning second line treatment 
-response to second line treatment 
-third line treatment with response 
-date of and state at last visit 
-data on patients lost at followed up were retrieved four times a year from Statistical 
Norway after consent from The Data Inspectorate. These data told whether the 
patients were alive or dead from any reason, but not the cause of death or the 
disease status for living patients. 
 
Updating of the database for patients no longer followed at NRH is a challenge, 
partly met by continuously registering policlinic notes and other reports from the local 
hospital. For patients not longer followed at NRH and for whom no information from 
the local hospital were available for the last year, these data were asked for at the 
local hospital during the last 1990´ies. 
 
The statistical analyses in all the studies were performed by using the SPSS for 
windows (Release 8.0, SPSS Inc., Chicago, IL., USA). The Kaplan-Meier method 
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(Kaplan et al.1958) was used for survival analysis, and the survival curves were 
compared by the logrank test (Peto et al. 1973). Multivariate analysis was performed 
by the Cox regression analysis. P<0.05 was considered as statistically significant, 
except in paper II in which p < 0.01 was used due to the high number of variables 
examined. Comparisons between groups were analyzed by the Mann-Whitney U-
test or the qui square test, whichever appropriate (paper III and IV). 
 
6.2.1 Patients with CNS manifestations after a diagnosis of non-Hodgkin’s 
lymphoma (paper I) 
This is a retrospective analysis. To retrieve information on symptoms at CNS 
diagnosis, to control and supplement the database on the given treatment and the 
basis for the CNS lymphoma diagnosis, all patient records were analyzed. As the 
survival data could be controlled by information from Statistics Norway and as the 
cause of death in patients with CNS manifestations in systemic lymphoma in nearly 
all cases were due to death from lymphoma, we used crude survival as the endpoint.  
 
Paper II 
The incidence and risk factors for CNS progression or relapse were examined 
retrospectively. Median observation time was 94 months (range 13-202 months) for 
the survivors. Performance status was assessed according to the Eastern 
Cooperative Oncology Group (ECOG) scale. The histological diagnosis was 
assessed according to the Kiel classification, and was not reviewed for this analysis. 
The relatively low number of T-cell lymphomas and the high numbers of low grade 
unclassified and high grade unclassified, reflects that some diagnoses were made 
before adequate immunohistology was available. 
 
The following factors were registered as potential risk factors for CNS involvement 
and entered into univariate analysis. 
Clinical variables: gender, ECOG performance status 0-1 versus 2-4, age below or 
above 60 years, bulky disease (>= 6 cm), stage, B- symptoms, IPI (Shipp et al. 
1993), age-adjusted IPI, B-or T-cell phenotype. 
Laboratory tests: erythrocyte sedimentation rate, lymphocyte count, hemoglobin, 
thrombocytes, LDH, alanine aminotransferase, gamma-glutamyltransferase, alkaline 
phosphatase, albumin, calsium. 
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Lymph node involvement at the following sites (including the spleen): neck, 
supraclavicular region, axilla, groin, mediastinum, retroperitoneum, iliacal region, 
spleen and the mesenterial lymph nodes. 
Extralymphatic involvement: testicles, lungs, pleura, liver, ventricle, small intestine, 
colorectal, pancreatic gland, mammary glands, gynecological sites, skin, thyroid 
gland, bone marrow, skeleton and ear, nose and throat regions, including the 
paranasal sinuses, parotid and submandibular glands. 
 
The basis for the CNS diagnosis is given in the paper. 
 
6.2.2 Cross-sectional follow-up study of patients with primary involvement of the 
gastric ventricle (paper III – IV)  
The survival analysis of all the 120 patients treated according to the protocol was 
retrospective. The 40 patients eligible for the study (see patients) were invited by 
mail to participate in the cross-sectional studies. They received two QOL 
questionnaires and patient information, and they returned the questionnaires 
together with the signed informed consent.  
The standard baseline questionnaire used in our study as well as in most European 
HRQOL studies on cancer patients is the EORTC QLQ-C30 (Aaronson et al. 1993). 
The questionnaire is described under Methods in paper III. The questionnaire is not 
very specific on symptoms like gastrointestinal complaints, fatigue and pain. 
Accordingly, modules with questions penetrating in depth into specific health 
problems have been constructed to be used in addition to the EORTC QLQ-C30 
questionnaire. Shortly before our study was planned, the gastric module STO22 was 
released and available as a questionnaire for our patient group. The STO22 
questionnaire is also described under Methods in Paper III.  
The median observation time for the 33 patients who met for a clinical examination 
was 102 months (range 34-148). The same patients were examined by case history, 
clinical examination, upper endoscopy and blood tests as described in paper IV. 
Surgical procedure performed and weight and height at diagnosis was retrieved from 
the patient records. The patients received the results from the study by mail and 
dietary advices if indicated by the blood tests. 
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7. RESULTS AND SUMMERY OF PAPERS 
 
7.1 Paper I
We examined crude survival from the time of the CNS diagnosis in 140 patients with 
systemic lymphoma, either at diagnosis of the systemic lymphoma, at progression 
during therapy or at relapse for patients who had achieved a complete remission. 
The impact of CNS related symptoms, age, histology and treatment from the CNS 
diagnosis were evaluated. The overall median survival for the 140 patients with 
SCNSL was only 2.6 months (95% CI: 2.1-3.2). Only 12 patients were alive in CR at 
the time of investigation. Patients with CNS involvement at diagnosis had the best 
prognosis (5.4 months), those who developed CNS disease during treatment the 
worst with a median survival of only 1.8 months (95% CI: 1.0-2.7). Notably, five of 
the eight patients consolidated with HDT are in CR. Paresis was the only symptom 
that predicted a shorter survival for SCNSL. Patients above 60 years of age with 
CNS involvement at progression or relapse also have a dismal prognosis. 
 Patients under 60 years of age with chemosensitive disease have better prospects, 
and they should be offered intensive chemo-radiotherapy including HDT with 
autologous stem cell support.  
 
      7.2 Paper II
The incidence and risk factors for CNS disease in consecutively treated patients 
were investigated. Among the 2514 patients with NHL, 106 patients (4.2%) 
developed CNS involvement during primary treatment (n=36) or at relapse (n=70). 
The percentage CNS recurrence according to the Kiel classification at 5 years were 
as follows: low grade, 2.8%; high grade, 4.3%; lymphoblastic or Burkitt`s lymphoma, 
24.4%. Multivariate analysis identified five independent risk factors, each present in 
> 5% of patients: elevated LDH, serum albumin < 35g/l, < 60 years of age, 
retroperitoneal lymph node involvement and involvement of more than one 
extranodal site. If four or five of these risk factors were present, the risk of CNS 
recurrence was in excess of 25% at 5 years. From 1990 onward, patients less than 
60 years of age with lesions in the paranasal sinuses, bone, epidural space, testis 
and in the bone marrow should receive CNS prophylaxis in the form of i.t 
methotrexate (some patients additionally received high dose methotrexate). When 
comparing patients given CNS prophylaxis with those who did not receive 
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prophylaxis, having the same risk factors, we could not detect any prophylactic 
effect of i.t. methotrexate.  
7.3 Paper III
In the time period from 1990-1999, 120 patients with gastric non-Hodgkin’s 
lymphoma were treated in a protocol involving primary gastric surgery at defined 
indications. The self-reported QOL (EORTC QLQ-30 and a gastric module) and 
objective findings from upper GI endoscopy were evaluated in patients less than 80 
years of age and in complete remission at a median of 102 months after treatment 
for primary gastric NHL at the Norwegian Radium Hospital. 36 patients (90%) 
completed the questionnaire and 33 (83%) met for endoscopy. The median age at 
follow up was 67 years. 
Seventeen of the patients who completed the questionnaires had a partial 
gastrectomi (PG), ten a total gastrectomi (TG) while nine were not operated on.  
General QOL was not different from population values according to the EORTC 
QLQ-30 module. The gastric module showed that patients treated with total 
gastrectomy reported more emotional problems, had more diarrhoea and more 
food-related problems (p<0.05) compared with the others. Gastroscopy was normal 
in 55% of the the patients who did not undergo total gastrectomy, oesophagoscopy 
in 69%. Four patients had Barret’s metaplasia. Conclusion: Total gastrectomi leads 
to an inferior QOL and should be avoided when possible. When examining QOL, it 
is important to use the relevant questionnaires. 
Survival analysis for the whole cohort of patients showed a disease specific 10-year 
survival of 88% and 40% for the patients with stage IE-IIE and stage IV, 
respectively. 
 
7.4 Paper IV
The nutritional status of 33 out of 40 eligible patients treated for gastric lymphoma 
according to a protocol involving primary surgery was examined at a cross-sectional 
study. The median observation time was 102 months after initiation of treatment, 
and the median age at follow up was 67 years. 
Seventeen patients had a partial gastrectomi (PG), nine a total gastrectomi (TG) 
and seven were not operated on. The patients in the TG group had a significant 
weight loss, lower storage iron content (s-ferritin and s-iron saturation), lower s-
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vitamin D, higher s-PTH and homocysteine than the other groups. It was concluded 
that if surgery is deemed necessary, a TG should be avoided whenever possible. 
The patients should be followed yearly for nutritional deficiencies and regular intake 
of vitamin D, vitamin B12, calcium, folic acid and iron should be considered.  
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8. DISCUSSION 
8.1 CNS manifestations in systemic non-Hodgkin’s lymphoma.
 CNS manifestations in non-Hodgkin’s lymphoma may be seen at diagnosis, during 
primary therapy or at progression or relapse after primary therapy.  
The incidence of CNS manifestations at diagnosis from our series of 30/2651 
patients (1.2%) is in line with the results from Bollen et al. (1997). The incidence at 
diagnosis varies most of all with the histological subtypes, and is highest in Burkitt’s 
lymphoma and Burkitt’s leukemia. In a review of three consecutive treatment 
protocols from the German Adult Acute Leukemia Group, Hoelzer et al (Hoelzer et 
al. 1996) report an incidence of 8/67 patients (12%) while the incidence in paediatric 
series of Burkitt lymphoma and leukaemia is reported to be 67/514 patients (13%) 
from a French study (Patte et al. 2001) and 96/1092 (8.8%) from a German series 
(Salzburg et al. 2007). Generally, the incidence of CNS manifestations at diagnosis 
in acute lymphoblastic leukemia (of which Burkitt’s leukemia constitutes only a small 
fraction) is reported to be 3-5% (Chamberlain et al. 2005). A CNS manifestation in 
follicular and other indolent lymphomas at diagnosis is at best scarce. A report of 
seven cases of indolent lymphomas includes one case with CNS manifestations at 
diagnosis, but this case was of small lymphocytic leukemia type (Spectre et al. 
2005). The other cases developed at various time points after initial diagnosis, and 
in four cases, a transformation to aggressive lymphoma was documented. A new 
entity described only recently, marginal zone lymphoma of the dura is described as a 
special form of PCNSL, but is located outside the CNS blood-brain barrier. They are 
usually localized and can be cured in a high percentage of cases by local therapy, 
surgery or radiotherapy or both (Iwamoto et al. 2006). 
There are numerous reports on the incidence of SCNS lymphoma at progression or 
relapse. Most investigations have been performed in aggressive lymphomas. The 
incidence amounts to approximately 5% in most series (Bos et al. 1998, van Besien 
et al. 1998) as in our investigation (Paper I and Paper II). However, some recent 
reports give lower incidences in the range of 1 – 2% (Boehme et al. 2007, Haioun et 
al. 2000, Arkenau et al. 2007). Possible explanations for these low figures are 
effective primary therapy with lower overall relapse rates due to effective therapy 
(Boehme et al. 2007, Haioun et al. 2000), to systemic and i.t. CNS prophylaxis to all 
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patients (Haioun et al. 2000) or i.t.methotrexate prophylaxis for high risk patients or 
shorter median follow up (Arkenau et al. 2007). In addition, Haioun et al. only 
registered patients with isolated CNS relapses. The incidence of SCNSL progression 
or relapse in L-NHL in our study was 2.8%. In a report of 7 cases of indolent 
lymphomas with SCNSL, four cases were related to transformation to aggressive 
lymphomas (Spectre et al. 2005). In our study, we performed a lymph node biopsy in 
14/37 patients with an original diagnosis of L-NHL and found histological 
transformation in nine (64%) of the cases. It is also well possible that the lymphoma 
cells of these patients invading the CNS had a more aggressive phenotype.  
 
The diagnosis of CNS manifestations is in the literature documented by cytological 
or cell count number of the CSF, by parenchymal manifestations by CT or MRI or by 
CNS-related symptoms like mental deterioration or nerve palsies as in our series. 
Recently, flow cytometric analysis of the CSF has been used and seems to increase 
the sensitivity of the leptomeningeal manifestations, at least by a factor of two 
(Hegde et al. 2005, Bromberg et al. 2007). 
 
CNS manifestations in NHL more often involve the leptomeninges than the 
parenchyma (Haioun et al. 2000, Kantarjian et al. 1988) as in our series. In a series 
of primary medistinal B-cell lymphomas, often involving contiguous extranodal 
manifestations in the mediastinum and lung metastasis, an increased relative 
frequency of parenchymal CNS disease was noted. They reviewed the relative 
frequencies as shown in Table 3 (Bishop et al. 1999). 
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Table 3. Sites of CNS Involvement in Large-Cell Lymphoma  
 
Leptomeningeal  Parenchymal  
Parenchymal and 
Leptomeningeal  
 
Study  
 
Total 
No. of 
Patients  
 
No. of 
Patients  % 
No. of 
Patients  % No. of Patients  %  
 
Bollen 1997 65 21 32 27 42 17 26 
Keldsen 
1996 
27 9 33 15 56 3 11 
Bashir 1991 14 11 79 3 21 0 0 
Wolf 1985 44 23 52 20 45 1 2 
Johnson 
1984 
29 23 79 3 10 3 10 
Levitt 1980 52 44 85 8 15 0 0 
Herman 
1979 
50 40 80 9 18 1 2 
Litam 1979 31 26 84 4 13 1 3 
Young 1979 20 16 80 2 10 2 10 
Law 1975 20 16 80 1 5 3 15 
Total 352 229 65 92 26 31 9 
Bishop et al. J Clin Oncol 1999 
 
The relative frequency of leptomeningeal / parenchymal disease of 2:1 is in line with the 
results from our investigations. In a recent review from the German High-Grade non-
Hodgkin’s Lymphoma Study Group (DSHNHL) of 1693 patients treated in randomized 
trials from 1993 – 2000, the relative frequency was inversed with 25 of 37 patients 
having intracerebral manifestations shown by radiological imaging.   
 
SCNSL may be part of a systemic disease progression or relapse, or alternatively an 
isolated lymphomatous manifestation. The distinction is important as it is logical to 
presume that the former manifestation is caused by inadequate primary systemic 
therapy while the latter manifestation might be avoided by effective CNS prophylaxis.  
The exact relative numbers is not given in the publications of our series, but is given in 
Table 4 together with the other six publications from the last decade with a reasonable 
number of patients at risk.  
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Table 4. The relative frequency of  CNS manifestations as isolated versus part of 
systemic relapse in patients with aggressive lymphoma (Lymphoblastic and Burkitt 
excluded) 
 
   Cohort CNS prophyl. No of patients Isolated    Part of systemic  Total 
Haioun et al. CR both    974  16 (1.6%)  6 (0.6%)  24 (2.2%) 
Van Besien All  systemic 605  20 (3.3%)  5 (0.7%)  25 (4.0%) 
Boehme All few  1693  15 (0.9%) 22 (1.3%)  37 (2.2%) 
Bos et al. CR no    193    2 (1%)     8 (4.1%)  10 (5.1%) 
Zinzani et al. CR not given   175    9 (5.2%)  not given 
Arkenau et al. All i.t.    259    0 (0.0%)   3 (1.1%)    3 (1.1%) 
 
 
8.1.1 Symptoms and signs at CNS diagnosis 
The symptoms of SCNSL are of course dependent on the site of the manifestations. 
In leptomeningeal manifestations, the three domains of neurological disturbances (and 
their symptoms) are (Chamberlain et al. 2005) 
1) The cerebral hemispheres (headache, mental status change, seizures, 
hemiparesis) 
2) Cranial nerves (double vision and loss of vision, hearing loss, facial numbness) 
3) Spinal cord and roots (weakness of extremities, most often lower, numbness and 
pain) 
In parenchymal manifestations, the most common symptoms are likely to be similar to 
those found in primary CNS lymphoma: Mental status change, headache, loss of 
function.  
 
The most common symptoms in our study (Paper I) are given in Table 3 in the 
manuscript. Bos et al. (1998) found mental changes in 40% and nerve palsies in nearly 
50% of their 25 cases similarly to the findings in two other small series (Hærni-Simon et 
al. 1987, Mead et al. 1986). Bashir et al. (1991) found personality changes to be the 
most prominent symptom. Exact relative numbers of symptoms are not given in the 
recent publications on larger series of patients.  
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8.1.2 Prognosis and treatment of SCNSL. 
A CNS manifestation in systemic NHL is considered to be a very serious event. In our 
retrospective analysis, only 12 out of 140 patients were long-term survivors, and the 
median survival was only 2.6 months. These figures are in line with other reports 
(Herman et al. 1979, Levitt et al. 1980, Mackintosh et al. 1982, Recht et al. 1988, Bashir 
et al. 1991). The prognosis was best for patients with a SCNSL diagnosis from the time 
of the initial NHL-diagnosis (5.4 months) and worst for those with CNS manifestations 
evolving during therapy (1.8 months). Slightly better outcome were reported from the 
French GELA group of 16 patients with isolated CNS relapse (Haioun et al. 2000) with a 
median survival of approximately 6 months. The German High-Grade non-Hodgkin’s 
Lymphoma Study Group reports of median patient survival of 4.4 months from the time 
of CNS recurrence. They found CNS recurrence to be an independent adverse risk 
factor for survival (Boehme et al. 2007). Furthermore, in the report from Spectre et al. 
(2005) on CNS manifestations in indolent lymphomas, the median survival was in the 
order of 2 years, implicating that the histology is important for the prognosis. In our 
study, we have not examined the prognostic value of L-NHL compared to H-NHL, partly 
because several of the low grade lymphomas had transformed to aggressive 
lymphomas at the time of CNS diagnosis. A comparison of the lymphoblastic and 
Burkitt’s lymphomas versus the rest showed, however an inferior prognosis for the 
former category. 
 
Treatment of SCNSL is a difficult theme. The treatment is bothersome in that it may 
have considerable side effects and it requires long hospital admittances at a time many 
want to spend the time at home with their families. The clinically relevant impact of the 
treatment on survival is questionable for many of the patients, but a few patients 
become long term survivors. It is therefore important to identify the patients with the 
best prognosis.  
We have not found other studies which have examined whether clinical symptoms 
predict survival. In the multivariate analysis of our study (Paper I) age, paresis or 
sensory loss, histology and time of CNS involvement were entered as prognostic 
variables. We found paresis and time of CNS involvement to be independent significant 
risk factors. Our findings that paresis or sensory loss is an independent risk factor for 
early death should be confirmed in an independent patient cohort. 
36
Treatment of leptomeningeal disease in systemic NHL has been reviewed by 
Chamberlain et al. (2005). Effective CNS directed therapy includes i.t. routed 
chemotherapy (methotrexate, prednisolone and cytarabine or combinations), high dose 
methotrexate with folic acid rescue, high dose cytarabine, high dose chemotherapy with 
autologous stem cell support (including the agents carmustine and melphalane) and 
high energy radiotherapy to the CNS axis or total body irradiation (TBI) with stem cell 
support. In addition, agents like etoposide and idarubicin have a not negligible 
penetration through the blood – brain barrier. Local, most often palliative radiotherapy 
given to intracerebral or intraspinal masses is often indicated. In cases where the CNS 
manifestations appear simultaneously with a systemic disease, the CNS directed 
therapy is most often combined with the most effective agents against lymphoma as 
indicated in the National treatment advice in Norway 
(www.legeforeningen.no/lymfomgruppen). We are not aware of larger prospective trials 
in this setting, but smaller retrospective and prospective analyses have been performed. 
In a pilot study from UK, a regimen containing idarubicin, high dose methotrexate with 
leukovorin rescue, high dose cytarabine, high dose dexamethasone and MTX and 
cytarabine given i.t. was given to patients with PCNSL and SCNSL (Moreton et al. 
2004). Of the 16 SCNSL patients, 12 achieved CR. Seven patients remained in CR at 
the time of this report with a median duration of follow-up of 24 months (range 18 to 57 
months). Small retrospective studies report rather disappointing results (Bokstein et al. 
2002, Kawamura et al. 2001). The value of radiotherapy after chemotherapy has been 
questioned (Magrath et al. 1996). In a retrospective study of 41 patients with SCNSL 
who all received systemic and intrathecal chemotherapy, a group of patients received 
additional CNS directed radiotherapy while a comparable group did not. Response to 
therapy did not differ whether patients received concomitant radiation or no CNS 
radiation. There were, however, considerably more side effects in the group receiving 
radiotherapy. In Norway, radiotherapy to the total CNS axis is usually reserved for 
patients achieving a complete remission after chemotherapy. 
 In our study, eight patients below the age of 60 years received high dose therapy with 
stem cell support after achieving a CR from CNS directed chemotherapy. All patients 
received some form of CNS directed radiotherapy, either as TBI as a part of the high 
dose therapy (five patients) or as total CNS irradiation (three patients). Five of these 
patients became long term survivors. Williams et al. (1994) retrospectively analyzed the 
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EBMT registry for patients given autologous stem cell transplantation with a history of 
SCNSL. 62 patients were registered, and those with a CNS manifestation at diagnosis 
had the better prognosis, as had those transplanted in CR. Patients given both i.t. 
chemotherapy and cranial irradiation had a better prognosis. In the 25 patients with 
isolated CNS relapse from the GELA study (Haioun et al. 2000), three patients are alive 
at four years of follow up. Two of these three patients received HDT. 
In a retrospective analysis from Stanford University (Alvarnas et al. 2000), 2 patients 
with PCNSL and 13 patients with SCNSL underwent HDT. Although there was a rather 
high morbidity and mortality rate, approximately 40% of the patients became long term 
survivors, and they conclude that “high-dose therapy with autologous stem cell support 
extended event free survival in patients with secondary CNS lymphoma and possibly in 
those with primary CNS NHL”. 
For most patients, a palliative goal for the treatment is most realistic. In this setting, 
repetitive i.t. chemotherapy and oral corticosteroid medication combined with local 
radiotherapy to sites giving rise to symptoms may be the best treatment choice 
(Chamberlain et al. 2005). To avoid the discomfort of repetitive lumbar punctures, an 
intraventricular reservoir is most often used in the US, but not in Europe. A new 
liposomal formulation of cytarabine (DepoCyte®) gives a prolonged CSF concentration 
of more than two weeks.  
In conclusion, the prognosis for patients with SCNSL is still unsatisfactory. Intensive 
therapy including HDT may improve long term survival, but more effective treatment 
regimens are needed. 
 
8.1.3 Risk factors for central nervous system recurrence in non-Hodgkin’s lymphoma 
and the value of CNS prophylaxis 
CNS prophylaxis is clearly warranted in Burkitt’s and lymphoblastic lymphomas based 
on the high CNS relapse rates of 17%-47% reported from several studies (Ersboll et al. 
1985, Liang et al. 1990, Keldsen et al. 1996, Bollen et al. 1997, Tomita et al. 2000) and 
from our study (Hollender et al. 2000 and 2002) and the reduced incidences in studies 
with both systemic and i.t. prophylaxis both in children and adults (Murphy et al. 1986, 
Patte et al. 1991, Magrath et al. 1996, Reiter et al. 1992, 1995, 1999, Soussain et al. 
1995, Mead et al. 2002, Pees et al. 1992, Smeland et al. 2004). In our study, 20/84 
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Burkitt’s lymphoma and lymphoblastic lymphoma patients (24.4%) had a CNS relapse. 
For patients with adequate prophylaxis, 19% had a CNS relapse while the number for 
those 14 patients who did not receive prophylaxis was as high as 78%.  
In indolent lymphomas, the CNS recurrence rate is low and prophylaxis is not 
considered warranted (Ersboll et al. 1985, Liang et al. 1990, Tomita et al. 2000). 
 
Risk factor analysis for CNS recurrence has been carried out in numerous studies on 
aggressive lymphomas to identify factors which should trigger the use of CNS 
prophylaxis. Earlier studies found specific sites to be related to a high risk of CNS 
recurrence like the ocular orbit, paranasal sinuses, bone, bone marrow and testis 
(Young et al. 1979, Liang et al. 1990, Al-Katib et al. 1984). More recent investigations 
have claimed that in multivariate analysis, the general extent of disease like elevated 
LDH, high IPI score and more than one extranodal localization are more important 
(Tomita et al. 2000, Bos et al. 1998, Haioun et al. 2000). In our study (paper II), the 
following factors, which all were present in more than five % of the cases, were found to 
be of prognostic value in multivariate analysis: low serum albumin, elevated serum LDH, 
involvement of retroperitoneal lymph node, age below 60 years and more than one 
extranodal site involved. If the patients had more than three of these factors at 
diagnosis, the risk of CNS recurrence was higher than 25%. CNS prophylaxis was 
advised for these patients, as well as for patients with testicular involvement with stage 
IIE or higher and for patients with paranasal sinus involvement. In a recent report from 
the German High-Grade Non-Hodgkin’s Lymphoma Study Group on 1693 patients with 
aggressive lymphoma, the CNS recurrence rate was as low as 2.2% although i.t. CNS 
prophylaxis was given to less than five % of the patients. Increased LDH and 
involvement of more than one extranodal site was confirmed as independent risk 
factors. The advice for i.t. CNS prophylaxis was cautiously advocated for elderly 
patients with elevated LDH and specific extranodal organ involvement like the bladder, 
liver and adrenals. In another recent study from UK on 259 patients with DLBCL 
(Arkenau et al. 2007), 19.7% of the patients received i.t. prophylaxis, based on site-
restricted guidelines (orbit, paranasal sinuses, testis, bone and bone marrow). The CNS 
recurrence rate was as low as 1.1%. The CNS relapse rate at three years was 
estimated to be 2.7%. The authors conclude that the i.t. prophylaxis guidelines used in 
this study are appropriate. 
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The value and mode of CNS prophylaxis in aggressive non-Burkitt’s – non-
lymphoblastic lymphomas is however, debated. In one study, the recurrence rate was 
high (26% at three years) although all patients received i.t. prohylaxis (Chua et al. 
2002). In another study, some patients were given i.t. prophylaxis and some not, 
dependent on the choice of the attending physician (Tomita et al. 2002). All six CNS 
relapses of 68 treated patients were in the group not receiving prophylaxis. In studies 
from the GELA group, both i.t. prophylaxis and consolidation with systemic high dose 
methotrexate, 3 g/m2 with folinic acid resque is given, and the relapse rate is low as 
previously reported (Haioun et al. 2000).  
Whether i.t. chemotherapy should be given intraventricularly through a surgically 
applied reservoir (Omaya catheter) or by the lumbar route is also debated. The 
concentrations acquired intraventricularly when chemotherapy is given through the 
lumbar route are considered largely inadequate while higher concentrations are found 
after intraventricular administration (Shapiro et al.1975).  
The recommended dose of high dose systemic methotrexate to achieve adequate 
concentrations is discussed in paper II, and is considered to be 3 g/m2. 
 
8.1.4 Central nervous system chemoprophylaxis in non-Hodgkin’s  lymphoma: current 
practice  
The practice concerning CNS prophylaxis varies highly between countries. In France, 
the ACVBP regimen has been used for more than 10 years, including i.t. methotrexate 
during induction chemotherapy and high dose cytarabine and methotrexate during 
consolidation for patients younger than 60-70 years (Tilly et al. 2003). In Germany, less 
than 5% of the patients have been given CNS prophylaxis, and if so only a small 
number of i.t. methotrexate administrations (Boehme et al. 2007). The practice in UK 
has recently been surveyed. The majority of centres used i.t. methotrexate prophylaxis, 
but generally in cases with specific extranodal involvement like the paranasal sinuses, 
testis, orbital cavity and bone marrow, and not for cases with high IPI score, elevated 
LDH and > one extranodalsite involved (Cheung et al. 2005). The practice in the Nordic 
countries was highly variable as surveyed by the Nordic Lymphoma Group 
(unpublished). Prophylaxis is generally not used in the US.  The varying practice in the 
Western world illustrates the lack of hard data concerning the value and “best practice” 
concerning CNS prophylaxis in aggressive non-Burkitt’s non-lymphoblastic lymphomas. 
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8.2 Primary gastric lymphomas
The GIT is the primary site of 30-40% of extranodal NHL and constitutes altogether 12% 
of NHL. The stomach is the most common site of GIT lymphomas (Glass et al. 1997). 
The most frequent histologies are the indolent marginal zone lymphomas and DLBCL. 
Marginal zone lymphomas may transform into DLBCL according to the WHO 
classification (Jaffe et al. 2001). Whether GIT lymphoma in stage IV disease is a 
primary extranodal disease or not can be discussed and may vary from case to case. 
We have chosen to include all patients with gastric involvement at the time of diagnosis. 
As discussed in papers III and IV, primary surgery was largely abandoned at the turn of 
the century. To investigate whether gastric surgery leads to long term morbidity, we 
decided to look into HRQOL and the nutritional status of the patients who were included 
in our protocol for GIT lymphomas. In this protocol, surgery of gastric lymphomas was a 
central mode of treatment in many cases. 
 
8.2.1 Quality of life after surgery for gastric lymphomas  
The quality of life was investigated by inviting the patients to a cross-sectional 
examination and by asking them to fill in and return by mail two validated 
questionnaires, the EORTC QLQ-C30, version 3 (Aaronson et al. 1993) and the STO22 
(Vickery et al. 2001).  
The EORTC QLQ-C30 questionnaire was developed by the EORTC Life Study Group, 
and has been thoroughly validated in different cancer populations. It is a 30 item 
questionnaire and is meant to evaluate physical, role, emotional, cognitive and social 
function as well as global QOL. The EORTC QLC-30 is a rather general questionnaire 
and may well be supplemented with cancer specific or organ specific questionnaires. 
The STO22 questionnaire was translated to Norwegian and released only shortly before 
this study took place. It is also developed by the EORTC QOL Study Group and 
evaluates the QOL of patients with gastric cancer and focuses on symptoms and side 
effects of gastric cancer. It encompasses 22 questions related to dysphagia, abdominal 
pain and discomfort, dietary restrictions, specific emotional problems, dry mouth, hair 
loss and body image. 
Interestingly, the questionnaires gave different results. There was no apparent 
difference between the categories no surgery, total gastrectomy and partial gastrectomy 
using the EORTC QOL-30 questionnaire. On the other hand, the results from the 
STO22 questionnaire showed increased digestive problems in the group of patients for 
41
whom total gastrectomi was a part of the treatment. The study underlines the 
importance of asking the right questions when HRQOL is assessed; if we had used only 
the EORTC QOL-30 questionnaire, the conclusion from the study would have been that 
also patients treated with total gastrectomi have a satisfactory QOL. When adding the 
STO22 questionnaire, our conclusion was that total gastrectomy should be avoided 
when possible when treating patients with gastric lymphomas.  The results from this 
study investigating primarily QOL are in line with those of the accompanying study 
investigating the nutritional status of the same group of patients. 
 
Another aspect included in the study was the objective findings at upper endoscopy. In 
four patients, Barrett’s metaplasia without dysplasia was diagnosed. One should bear in 
mind the increased frequency of gastric carcinomas at the surgical resection border in 
cases of Barret’s dysplasia, and controls with upper endoscopy should be performed at 
least with a three-year interval (Sampliner 2002).  
 
8.2.2 Long term effects on nutritional status after surgical treatment of gastric lymphoma 
and consequences for advice concerning nutritional supplementation 
The patients who were operated on with a total gastrectomy, had significant weight loss. 
They also had a lower storage iron content, lower s-vitamin D, higher s-PTH and 
homocysteine than those who had a partial gastrectomy or were not operated on. 
We have found no literature on this topic for lymphoma patients.  
A strength of the investigation is the rather long follow-up period after surgery. 
Treatment differed between patients (total versus partial gastrectomy versus 
conservative treatment), giving small number of patients in each treatment group. On 
the other hand, this gave us the opportunity to compare the long term effects of the 
different treatment options. Another advantage for this analysis was the fact that the 
body mass index and most relevant blood tests were registered for each patient in the 
patient record at the time of the diagnosis. The demography in Norway made it possible 
to reach most patients by mail.  
 
After gastric surgery, information concerning dietary intake should be given before the 
patient leaves the hospital. The information can be given by the doctor, the nurse or the 
dietician; it is important to have good routines. We also advice that the information is 
repeated routinely after one year, five and ten years combined with biochemical control 
42
of vitamin D, PTH, calcium, iron, folic acid and homocysteine. If deficiencies or weight 
loss is detected, the controls should be performed more frequently. Combined oral and 
written advice is preferable.  
 
Vitamin B12 / folic acid / homocysteine 
It is advised to give Vitamin B12 injections every 3. month for patients treated with total 
or partial gastrectomy. When partial gastrectomy ad modum Bilroth I has been 
performed, serum level of vitamin B12 can be controlled to evaluate whether vitamin B12 
substitution is necessary or not. 
Supplementation with B-vitamins, in particular with folic acid, is an efficient, safe, and 
inexpensive means to reduce an elevated homocysteine level. This may aid in the 
prevention of cardiovascular disease. (reviewed in Refsum et al. 1998).  
Sakuta et al. (2005) compared plasma total homocysteine, vitamin B12 and folic acid of 
31 male patients who had undergone gastrectomy with those of 31 control male 
subjects. None of them were taking folic acid or vitamin B12. They concluded that 
hyperhomocysteinemia is a relatively common clinical feature of gastrectomized male 
patients, especially for those who had undergone gastrectomy for stomach cancer.  
Folic acid of the two groups was comparable. Vitamin B12 was lower for the 
gastrectomized patients. 
 
Iron For iron deficiency, we recommend iron supplementation together with vitamin C 
between meals for better absorption. Tea and coffee contains polyfenol which inhibits 
the absorption of iron. Calcium, i.e. in milk, also reduces the absorption of iron. Sources 
of iron in the Norwegian diet are meat, bread, sweet brown cheese made of goat`s milk 
(fortified with iron), liver paste and green vegetables. 
 
Vitamin D  
 
Vitamin D deficiencies and consequences 
 
Osteopenia / osteoporosis
Vitamin D deficiency leads to reduced calcium absorption, resulting in hypocalcaemia 
and increased PTH. The increased PTH induces increased renal secretion of phosphate 
and hypophosphataemia. Consequently, too little calcium and phosphate will be 
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deposited in the bone matrix, and the growth and mineralization of the skeleton will be 
impaired. Small children and the elderly need supplement of vitamin D to avoid rickets 
(defective mineralization) and osteomalacia (demineralization of the skeleton) 
respectively. Osteomalacia results in a weak skeleton with less structural support, which 
easily fractures. Osteoporosis is preceded by osteopenia, and defined as reduced 
density of the bone, due to loss of the bone tissue. Mosekilde et al. (review article 2005) 
concludes that vitamin D deficiency is an established risk factor for osteoporosis, falls 
and fractures. The population of Oslo has the highest incidence reported of hip fracture 
and forearm fractures. Lofthus et al. (2007) conclude that the reasons for the high 
incidence of osteoporotic fractures in Norway are not clear, and different mechanisms 
for the pathogenesis of osteoporosis related to genetics as well as environmental 
determinants have to be addressed. Kaastad et al. (1998), found differences in the 
incidence of hip fracture between the different city regions in Oslo corresponding to 
differences in the mortality and socioeconomic status. They conclude that further 
studies are needed to investigate the causes for these differences.  
 
Heart disease, diabetes mellitus and cancer 
Chronic vitamin D deficiency may increase the risk of hypertension, multiple sclerosis, 
cancers of the colon, prostate, breast and type 1 diabetes (Holick 2004). Also Mosekilde 
(2005) review epidemiological studies suggesting that vitamin D insufficiency is related 
to breast, prostate and colon cancers, type 2 diabetes, and cardiovascular disorders 
including hypertension. The mechanisms for this are probably due to vitamin D`s 
influence on cell differentiation and tumour progression (reviewed in Moan et al. 2006, 
Mosekilde 2005).  
 
Robsahm et al. (2004) studied 115 096 cases of breast-, colon- and prostate cancer, 
and they observed a significant variation in prognosis by season of diagnosis. Diagnosis 
during summer and fall, the season with the highest level of vitamin D3, revealed the 
lowest risk of cancer death. They suggest that a high level of vitamin D3 at the time of 
diagnosis, and thus, during cancer treatment, may improve prognosis of the three 
cancer types studied. The results support the suggestion that vitamin D3 suppresses 
cancer progression through several growth inhibition mechanisms. The use of UV 
radiation might be a supplement to cancer treatment without the risk of hypercalcemia 
(due to vitamin D`s hypercalcemic potency). Porojnicu et al. (2007) also finds a higher 
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survival for summer and autumn diagnosis for Hodgkin`s lymphoma in addition to the 
above mentioned cancers. 
 
The above referred studies indicates that vitamin D is important in cancer biology, and it 
is of great interest to follow future studies regarding it`s role in prevention and treatment 
of cancer.  
 
Recommended daily intake of vitamin D 
The Directorate for Health and Social affairs, Department for Nutrition, generally 
recommend daily intake of vitamin D as follows: 10 g from 6 to 23 months and for 
those over 60 years, and 7,5 g for those between 2 and 60 years. Serum vitamin D 
should be > 50 nmol/l. These recommendations are based on The Nordic Nutrition 
recommendation 2004 – integrating nutrition and physical activity.  
Vieth et al. (2004) conclude that 25(OH) D concentrations higher than 70 nmol/L is 
physiological and beneficial to various aspects of human health. According to Moan 
(2006) optimal levels of calcidiol are probably higher, in the range 100-250 nmol/l.  
Vitamin D exists naturally in fatty fish such as salmon, trout, mackerel and herring, cod 
liver oil and egg yolk. Some food is vitamin D fortified: margarines and extra low fat milk. 
(Holick et al. 2004). For many people, it is difficult to get enough vitamin D by eating 
these foods; it is adviced to eat fatty fish at least 3-4 times / week. Five ml cod-liver oil 
contains 10 g (=400 IU) vitamin D and is a valuable source of vitamin D. Holick et al. 
(2004) conclude that the recommended intakes for vitamin D are inadequate, and, in the 
absence of exposure to sunlight, a minimum of 1000 IU vitamin D/d is required to 
maintain a healthy concentration of 25(OH)D in the blood.  
Robsahm et al. (2004) refers to a Norwegian report from the National Council on 
Nutrition and Physical Activity which concludes that Norwegian healthy adults have an 
adequate level of vitamin D3  during the summer, as far as bone metabolism is 
concerned. However, the level required to reduce the neoplastic progression to cancer 
is unknown.  
 
Calcium  
To prevent osteoporosis; a daily intake of calcium 800 mg for young people and at least 
1000 mg for the elderly, in combination with vitamin D is recommended. The lack of 
production of estrogens for menopausal women is the most important cause for the loss 
45
of bone mass. For men, the lack of androgen production, use of glucocorticoids and 
excess alcohol intake are important factors. Smoking and inactivity also promotes 
osteoporosis.  For those who already have established osteoporosis, a daily intake of 
calcium (1-1,5 g/day) and vitamin D (800 IU/day = 20 μ/day) is recommended. 
Bisphosphonates reduces the activity of the osteoclasts and this treatment reduces the 
incidence of fractures, especially in women ( www.legemiddelhandboka.no).  
Moyad (2003) also recommends that calcium and vitamin D supplements are taken 
together because they act synergistically to reduce fracture risk. 
 
8.2.3 For which patients with gastric lymphomas should primary surgery still be 
considered?  
According to our protocol, patients with gastric lymphomas were evaluated for primary 
surgery for the following reasons: 
1. Diagnostic workout. According to Fleming (1982) and other authors, a correct 
diagnosis and stage was at that time made in a minority of the patients before 
surgery. The biopsies taken at gastroscopy were often too small and of inferior 
quality.  
2. Treat or prevent excessive bleeding or perforation in lymphomas extending to the 
serosa, either before treatment or as a complication to chemotherapy.  
3. Curative treatment of early-stage lymphomas.  
 
Results from studies from the last decade have shed new light on these issues.  
1. During the last decades, histopathological diagnosis based on endoscopic 
biopsies has improved greatly, and today a surgical biopsy is in most cases 
unnecessary. Immunohistochemistry will in most cases discern better between 
lymphoma and carcinoma, and ultrasonography adds information to CT scans 
regarding degree of gastric wall involvement. In some centres, endoscopic 
ultrasound is used in the staging procedure. In a large randomized study in 
Mexico, a correct diagnosis was reported established without the use of surgery 
in all of the 1160 included patient (Avilés et al. 2004). These data are not in 
concordance with the results from a multicentre study from the German-Austrian 
gastrointestinal lymphoma study group, in which primary surgery was used for all 
non-MALT stage IE cases. Endoscopic-bioptic typing and grading and clinical 
staging were accurate in only 73% and 70%, respectively, based on the 
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histopathology of resected specimens. If primary chemotherapy is used, the 
prognostic difference between stages IE and IIE may be of minor importance, 
however (Avilés et al. 2004).  
2. Today, experience from prospective studies has shown that the complications 
after primary chemotherapy are fewer than in previous studies and may be 
considered a safe procedure in most cases. In the German multicentre studies 
01/92 and 02/96 the complication rates were low (Koch et al. 2001, Koch et al. 
2005). In both studies, primary surgery or a non-surgical conservative approach 
was used according to the choice of the treating physicians. In the former study, 
there is only one reported death from perforation out of 106 patients treated 
conservatively, and there were no complication from serious bleeding. In the 
study of Avilés (2004), primary surgery was not performed to control bleeding or 
due to gastric wall perforation in any of the cases.  In a smaller study, Kochi et al. 
(2007) treated ten patients with primary gastric lymphoma stage IE-IIE 
prospectively with primary intensive combination chemotherapy followed by 
extensive surgery. No gastric complications were seen during chemotherapy. In 
all resected specimens, a complete histological remission was seen. No relapses 
have occurred, but surgical complications were seen in three cases. On the other 
hand, Spectre et al. (2006) report of gastric complication in 18/73 patients during 
primary chemotherapy for PGL of whom six were operated. The complications 
were divided between gastric outlet obstruction and bleeding complication. No 
perforations were seen.  
3. Treatment of stage IE and IIE NHL of the gastric ventricle may in principle follow 
the principles of localized nodal lymphoma: Aggressive lymphomas are in 
principle curable with combination immuno-chemotherapy. Systemic therapy 
thereby reduces the risk of a relapse from minimal disease outside the radiation 
field or the surgically removed macroscopic tumour. For indolent lymphomas, 
systemic conventional therapy is not curative and is thus usually not given in 
addition to local treatment (radiation therapy or surgery).  
In aggressive lymphomas, long term follow up of the prospective randomized 
SWOG study, comparing eight courses of CHOP to three courses plus 
radiotherapy indicates that radiotherapy does not seem to be advantageous in 
the long run (Miller et al. 2001) as indicated from the first publication (Miller et al. 
1998). Similarly, the French study comparing the more intensive ACVBP regimen 
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to combined CHOP-radiotherapy showed a better survival for the chemotherapy-
only arm (Reyes et al. 2005). Similar results seem to evolve from studies on 
gastric intestinal lymphomas; chemotherapy only may be at least as good as 
combined surgery and radiotherapy (Avilés et al. 2004, Al Akwaa et al. 2004, 
Binn et al. 2003, Koch et al. 2001, Koch et al. 2005). Furthermore, as for 
histologically aggressive localized nodal lymphomas surgery and / or 
radiotherapy without chemotherapy is clearly inferior to regimen in which 
chemotherapy is added.  
 
As for nodal DLBCL, limited disease, one may argue that when intensive 
combined immuno-chemotherapy is used, there may no longer be necessary to 
give radiotherapy to limited stage PGL as shown by Avilés et al. (2004) in a 
randomized fashion and by the excellent results in a phase II study by Raderer et 
al. (2000). Koch et al. argue that in PGL DLBCL, there is a mixture of up to 1/3 of 
the malignant lymphoid cells composed of indolent lymphoma, not eradicated by 
chemotherapy (Koch et al. 2006). Furthermore, in Helicobacter positive DLBCL, 
antibiotic treatment has in small series been given successfully (Chen et al. 
2005) and should be explored further, and may improve the cure rate of this 
disease.  
 
In indolent PGL, most cases are of the marginal zone type. In stage IE, 
helicobacter pylori eradication has evolved as the treatment of choice (Bertoni et 
al. 2005, Fischbach et al. 2007), curing more than two third of the patients while 
the majority of the remaining ones can be followed without further treatment for 
years. For stage IIE disease, radiotherapy is the preferred modality among the 
majority of haemato-oncology experts, further diminishing the role of primary 
surgery.  
 
The long term morbidity after total gastrectomy shown in our study is in line with 
results shown after gastrectomy for gastric carcinomas (Horvath et al. 2001, 
Svedlund et al. 1997), further strengthening the argument for a conservative 
approach. However, patients having a partial gastrectomy seem to have a decent 
quality of life, so that surgery should not be avoided for any price if the 
48
indications for operation are strong: profuse bleeding, perforation or obstruction 
outlet. (Spectre et al. 2006).   
 
9. CONCLUSIONS 
1. In patients with NHL with systemic involvement of the CNS, the overall median 
survival was only 2,6 months in our material. Patients above 60 years of age with 
CNS involvement at progression or relapse, and those with paresis at the time of 
CNS diagnosis have a dismal prognosis, and supportive therapy only should be 
considered. Patients under 60 years with chemosensitive disease have better 
prognosis, and should be offered intensive chemo-radiotherapy including HDT 
with ASCS. 
2. The risk of CNS involvement for patients with NHL was low (2,8%) in low-grade 
NHL. In high-grade NHL, lymphoblastic and Burkitt`s NHL, patients had a high 
risk of CNS recurrence (24,4 %) at 5 years, for the other patients with NHL the 
risk was 5,2%. We recommend CNS prophylaxis for patients with either Burkitt`s 
or lymphoblastic lymphoma with intensive chemotherapy including systemic and 
i.t. methotrexate. Those with other types of H-NHL should receive CNS 
prophylaxis if four of the five following risk factors are present: elevated serum 
LDH, serum albumin < 35 g/l, < 60 years of age, retroperitoneal lymph node 
involvement or involvement of more than one extranodal site. 
3. Patients in CR after treatment for primary gastric NHL reported a general QOL 
not different from population values according to the EORTC QLQ-30 module. In 
the gastric module (EORTC STO22), however, patients treated with total 
gastrectomy reported poorer emotional functions, more diarrhoea and more food-
related problems, compared to those who had a partial gastrectomy or those who 
did not undergo surgery. Total gastrectomy should be avoided when possible. 
4. Patients with gastric NHL who had a total gastrectomy, had a significant weight 
loss. They also had a lower storage iron content, lower s-vitamin D, higher s-PTH 
and homocysteine than those who had a partial gastrectomy or no surgery. If 
surgery is necessary for gastric lymphomas, a partial gastrectomy should be 
performed when possible. The patients should receive dietary advice and follow-
up concerning intake of vitamin D-and B12, calcium, folate and iron. 
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10.     ERRATUM 
 
 
Paper II 
Page 1099, Background, results 
…the proportion with CNS involvement at 5 years was 4.3% (not 5.2%).  
 
Paper IV: 
 
Page 675, Table I: 
Median age (range) wrong: 56 (37-75) 
                                 right: 67 ( 47-79) 
 
   page 676: 
   wrong: 2-hydroxyvitamin D and PTH 
  
   right: 25- hydroxyvitamin D and PTH 
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